Junichiro Yuda

1.1k total citations
43 papers, 566 citations indexed

About

Junichiro Yuda is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Junichiro Yuda has authored 43 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Hematology and 15 papers in Molecular Biology. Recurrent topics in Junichiro Yuda's work include CAR-T cell therapy research (13 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Junichiro Yuda is often cited by papers focused on CAR-T cell therapy research (13 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Junichiro Yuda collaborates with scholars based in Japan, United States and Spain. Junichiro Yuda's co-authors include Yosuke Minami, Toshihiro Miyamoto, Koichi Akashi, Yoshikane Kikushige, Takahiro Shima, Katsuto Takenaka, Hiromi Iwasaki, Siamak Jabbarzadeh‐Tabrizi, Ayano Yurino and Shin‐ichiro Takayanagi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Junichiro Yuda

35 papers receiving 563 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junichiro Yuda Japan 10 289 268 198 180 63 43 566
Chelsea J. Gudgeon United States 11 177 0.6× 308 1.1× 220 1.1× 206 1.1× 32 0.5× 16 532
Jing Lai China 14 307 1.1× 241 0.9× 178 0.9× 158 0.9× 47 0.7× 38 571
Ángel Ramírez Páyer Spain 12 286 1.0× 263 1.0× 162 0.8× 177 1.0× 172 2.7× 33 609
Courtney DiNardo United States 2 258 0.9× 213 0.8× 254 1.3× 363 2.0× 109 1.7× 3 604
Maria J. Carnicer Spain 11 148 0.5× 183 0.7× 333 1.7× 162 0.9× 62 1.0× 18 611
Yuji Shimura Japan 15 190 0.7× 226 0.8× 357 1.8× 227 1.3× 100 1.6× 69 704
Myriam Foglietta Italy 16 573 2.0× 357 1.3× 162 0.8× 194 1.1× 102 1.6× 29 805
Frauke M. Schnorfeil Germany 7 282 1.0× 371 1.4× 164 0.8× 202 1.1× 32 0.5× 9 556
Tina Nuebling Germany 9 270 0.9× 247 0.9× 132 0.7× 106 0.6× 37 0.6× 13 455
Andrea N. Marcogliese United States 9 113 0.4× 187 0.7× 158 0.8× 78 0.4× 32 0.5× 23 381

Countries citing papers authored by Junichiro Yuda

Since Specialization
Citations

This map shows the geographic impact of Junichiro Yuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junichiro Yuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junichiro Yuda more than expected).

Fields of papers citing papers by Junichiro Yuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junichiro Yuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junichiro Yuda. The network helps show where Junichiro Yuda may publish in the future.

Co-authorship network of co-authors of Junichiro Yuda

This figure shows the co-authorship network connecting the top 25 collaborators of Junichiro Yuda. A scholar is included among the top collaborators of Junichiro Yuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junichiro Yuda. Junichiro Yuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iida, Shinsuke, Kazutaka Sunami, Shigeki Ito, et al.. (2025). Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM. International Journal of Hematology. 122(3). 421–433.
2.
Naito, Yoichi, Nozomu Fuse, Masashi Wakabayashi, et al.. (2025). Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr). Frontiers in Oncology. 15. 1633324–1633324.
3.
4.
Izutsu, Koji, Junichiro Yuda, Hirokazu Nagai, et al.. (2025). Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial. International Journal of Clinical Oncology. 30(8). 1631–1640. 2 indexed citations
5.
Yuda, Junichiro, et al.. (2024). Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan. International Journal of Clinical Oncology. 30(1). 157–167.
6.
Yuda, Junichiro, et al.. (2024). BP1223, a Novel T Cell Engager Targeting CD39 for Potent Antitumor Activity in Acute Myeloid Leukemia. Blood. 144(Supplement 1). 4146–4146. 1 indexed citations
7.
Hashimoto, Tadayoshi, Yoshiaki Nakamura, Eiji Oki, et al.. (2024). Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay. International Journal of Clinical Oncology. 29(5). 495–511. 10 indexed citations
8.
Chong, Elise A., Junichiro Yuda, Koji Izutsu, et al.. (2024). A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.. Journal of Clinical Oncology. 42(16_suppl). TPS7091–TPS7091. 3 indexed citations
9.
Guo, Yong‐Mei, et al.. (2024). Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment. SHILAP Revista de lepidopterología. 5(3). 642–645. 1 indexed citations
10.
Tahir, Stephen K., Emiliano Calvo, Benedito A. Carneiro, et al.. (2023). Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 141(17). 2114–2126. 9 indexed citations
11.
Izutsu, Koji, Junichiro Yuda, Hirokazu Nagai, et al.. (2023). Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma. Cancer Science. 114(12). 4643–4653. 12 indexed citations
12.
Itahashi, Kota, Takuma Irie, Junichiro Yuda, et al.. (2022). BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Science Immunology. 7(76). eabk0957–eabk0957. 60 indexed citations
13.
14.
Mori, Yasuo, Goichi Yoshimoto, Takuji Yamauchi, et al.. (2021). Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology. 115(1). 96–106. 2 indexed citations
15.
Tabata, Rikako, et al.. (2021). Emerging Immunotherapy for Acute Myeloid Leukemia. International Journal of Molecular Sciences. 22(4). 1944–1944. 51 indexed citations
16.
Jongen‐Lavrencic, Mojca, Junichiro Yuda, Rogier Mous, et al.. (2020). AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 20. S177–S177. 2 indexed citations
17.
18.
Inoue, Ai, Haruka Shinohara, Ken‐ichi Miyamoto, et al.. (2018). Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence. International Journal of Hematology. 108(4). 365–370. 17 indexed citations
19.
Shima, Takahiro, Sayuri Miyauchi, D. T. Johnson, et al.. (2017). CPSF1 Regulates AML1-ETO Fusion Gene Polyadenylation and Stability in t(8;21) Acute Myelogenous Leukemia. Blood. 130. 2498–2498. 2 indexed citations
20.
Kikushige, Yoshikane, Toshihiro Miyamoto, Junichiro Yuda, et al.. (2015). A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. Cell stem cell. 17(3). 341–352. 211 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chelsea J. Gudgeon Breakdown of academic impact, for papers by Jing Lai Breakdown of academic impact, for papers by Ángel Ramírez Páyer Breakdown of academic impact, for papers by Courtney DiNardo Breakdown of academic impact, for papers by Maria J. Carnicer Breakdown of academic impact, for papers by Yuji Shimura Breakdown of academic impact, for papers by Myriam Foglietta Breakdown of academic impact, for papers by Frauke M. Schnorfeil Breakdown of academic impact, for papers by Tina Nuebling Breakdown of academic impact, for papers by Andrea N. Marcogliese
Rankless by CCL
2026